DRRX News and Press, DURECT Corporation From 04/30/24

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis PR Newswire CUPERTINO, Calif. , April 30, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage b...

2024-03-27 18:07:09 ET DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript March 27, 2024, 04:30 PM ET Company Participants Tim Papp - CFO Jim Brown - CEO Norman Sussman - CMO Keith Lui - SVP, Business Development, Commercial, Medical Affairs Con...

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire - Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, M...

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...

2024-03-26 17:35:35 ET More on DURECT DURECT and Charles River enter agreement for alzet in U.S., Canada Seeking Alpha’s Quant Rating on DURECT Historical earnings data for DURECT Financial information for DURECT Read the full article on Seek...

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif. , March 20, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering th...

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada PR Newswire Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and A...